Baseline characteristics of the study sample
| Characteristics | Complete Remission at Rituximab Initiation | Partial Remission at Rituximab Initiation | Combined |
|---|---|---|---|
| Number | 17 | 22 | 39 |
| Number with anti-PR3/anti-MPO | 11/6 | 13/9 | 24/15 |
| Median age (range) | 63 (25 to 87) | 59.5 (39 to 88) | 60 (25 to 88) |
| Women (percent) | 6 (35%) | 14 (64%) | 20 (51%) |
| Median BVAS/WG at AAV diagnosis (range) | 5 (1 to 8) | 4.5 (1 to 9) | 5 (1 to 9) |
| Median BVAS/WG at rituximab initiation (range) | 0 (NA) | 2 (1 to 4) | 1 (1 to 4) |
| Median duration before rituximab, months (range) | 51 (3 to 282) | 71.5 (3 to 506) | 67 (3 to 506) |
| Number of relapses at rituximab initiation | |||
| 0 | 8 | 5 | 13 |
| 1 to 2 | 7 | 11 | 18 |
| >2 | 2 | 6 | 8 |
| 12 months of follow-up available | 11 | 8 | 19 |
| 24 months of follow-up available | 6 | 14 | 20 |
NA, not applicable.